Trial Profile
Multiple ascending dose study of ABT 122 in patients with rheumatic arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jan 2017
Price :
$35
*
At a glance
- Drugs Remtolumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 23 Jul 2015 New trial record
- 13 Jun 2015 Results presented (in pooled results of 3 phase I trials) at the 16th Annual Congress of the European League Against Rheumatism.